ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0110

SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses

Yuka Nakao1, Astha Patel1, Bahram Razani2, Steven yu1, Steven Lazarevsky2, Marlys Fassett2 and Judith Ashouri1, 1University of California, San Francisco, San Francisco, CA, 2UCSF Department of Dermatology, San Francisco, CA

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, immunology, Mouse Models, Other, Psoriatic arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0098–0114) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are chronic immune-mediated diseases affecting millions, yet early immunologic triggers remain poorly defined. Therapies targeting TNFα, IL-17, and IL-23 help many, but inadequate or transient responses highlight the need to understand upstream mechanisms. CD4⁺ T cells are central to disease, but early events are hard to study in humans due to genetic variability, late-stage clinical presentation, and limited tissue access. The SKG mouse, with a hypomorphic Zap70 mutation impairing negative selection, develops CD4⁺ T cell–driven, spontaneous and environmentally induced erosive arthritis with features of RA (RF⁺, ACPA⁺, pneumonitis) and spondyloarthritis (skin, eye, gut inflammation, enthesitis). While joint disease is well described, associated skin inflammation is not. Our data reveal psoriatic-like changes reflecting key features of human Pso and PsA. This study aims to define the molecular and cellular mechanisms of Pso skin disease in SKG and characterize the pathogenic TCR repertoire involved.

Methods: Disease was induced by intraperitoneal injection of zymosan into SKG mice or by adoptive transfer of SKG CD4⁺ T cells into SCID hosts. Psoriasis-like skin disease incidence and clinical arthritis scores were monitored. Skin was evaluated by histology and flow cytometry to assess immune cell infiltration and TCR Vβ repertoire; group differences were analyzed by t-tests and exact permutation tests.

Results: We found that SKG mice develop Pso-like skin inflammation in response to environmental triggers (e.g., zymosan), histologically mirroring human disease with acanthosis, hyperkeratosis, neutrophilic micro abscesses, and lymphohistiocytic infiltrates. We demonstrate for the first time that SKG CD4⁺ T cells alone are sufficient to induce Pso in SCID hosts (Fig. 1), establishing a CD4⁺ T cell–dependent mechanism of pathogenesis. Flow cytometry shows increased conventional dendritic cells (p=0.02), a trend toward greater neutrophil infiltration and expansion of Vγ2⁺ CD4⁺ T cells—key IL-17 producers implicated in Pso. We identify pathogenic CD4⁺ T cells enriched for TCR Vβ chains recognizing superantigens (Sags) from an endogenous retrovirus (ERV)—genomic elements that incorporated into the mammalian genome in ancient times and shape innate and adaptive immunity. These Sag-reactive TCRs are significantly enriched in Pso skin relative to peripheral lymphoid organs, while non-cognate Vβs show no enrichment (Fig. 2), supporting an ERV-driven mechanism of tissue-specific autoimmunity.

Conclusion: SKG mice model the chronicity and immune complexity of human Pso, integrating innate (e.g., neutrophil accumulation) and adaptive (CD4⁺ T cell–driven) pathways without exogenous chemicals. The discovery of Sag-reactive CD4⁺ T cells recognizing ERV-encoded superantigens in affected skin defines a novel molecular axis of psoriatic autoimmunity. This model provides a robust platform to study disease initiation, antigen-specific responses, and test targeted therapies—advancing translational understanding of Pso and PsA.

Supporting image 1Figure 1. Microbiota are required for arthritis development in SKG mice. Germ-free (GF) SKG mice (n=8) and conventionalized GF SKG mice (n=9) were injected intraperitoneally with zymosan and monitored over time for clinical arthritis scores. (A) Longitudinal arthritis scores are shown for each group. (B) Cumulative disease burden, measured by area under the curve (AUC) of arthritis scores, was significantly higher in conventionalized mice (Wilcoxon test, p = 0.0072).

Supporting image 2Figure 2. Sag-reactive T cells accumulate in SKG psoriatic skin. Mean frequency (± SEM) of SKG CD4 T cells with Sag-reactive TCR Vβ3 (A) or non-cognate Vβ8 (B) protein usage determined by flow cytometry in LN, joints & skin 5 weeks post zymosan. P value < 0.05 (*) calculated from exact permutation test (A-B).


Disclosures: Y. Nakao: None; A. Patel: None; B. Razani: None; S. yu: None; S. Lazarevsky: None; M. Fassett: Boehringer-Ingelheim, 2, Sanofi-Regeneron, 1; J. Ashouri: None.

To cite this abstract in AMA style:

Nakao Y, Patel A, Razani B, yu S, Lazarevsky S, Fassett M, Ashouri J. SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/skg-mice-develop-cd4%e2%81%ba-t-cell-driven-psoriasis-and-enable-study-of-endogenous-antigen-specific-responses/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/skg-mice-develop-cd4%e2%81%ba-t-cell-driven-psoriasis-and-enable-study-of-endogenous-antigen-specific-responses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology